EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction

Tomohiro Shimizu, Tetsuji Morishita, Hiroyasu Uzui, Yusuke Sato, Tatsuhiro Kataoka, Machiko Miyoshi, Junya Yamaguchi, Yuichiro Shiomi, Hiroyuki Ikeda, Naoto Tama, Kanae Hasegawa, Kentaro Ishida und 1 weitere

Heart and Vessels · 2025

DOI: 10.1007/s00380-024-02473-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart and Vessels, 2025. Verfasst von Tomohiro Shimizu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka Eiheiji-cho, Yoshida-gun, Fukui, …. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Myocardial Infarction, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, University of Fukui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examined the anti-inflammatory and endothelial function-enhancing effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor therapy in the early phase after acute myocardial infarction (AMI) by assessing changes in tumor necrosis factor-α (TNF-α) levels and the l -arginine/asymmetric-dimethylarginine (ADMA) ratio. This retrospective, single-center cohort study included patients who underwent successful timely primary percutaneous coronary intervention (PCI) for first-onset AMI between September 2017 and March 2018. The PCSK9 inhibitor group comprised patients who received 75 mg alirocumab up to 7 days after AMI, while the standard therapy group comprised patients who did not. We evaluated the change in TNF-α levels and the l -arginine/ADMA ratio at the time of hospital admission and prior to discharge. PCSK9 inhibitor therapy in the early phase after AMI suppressed TNF-α levels (standard therapy group, 1.64 ± 2.14 pg/mL vs. PCSK9 inhibitor group, 0.26 ± 0.33 pg/mL; p = 0.033) and increased the L-arginine/ADMA ratio (standard therapy group, − 13.0 ± 39.7 vs. PCSK9 inhibitor group, 23.2 ± 39.7; p = 0.042). Upon multiple regression analysis adjusted for sex, age, and peak creatine kinase levels, PCSK9 inhibitor therapy was associated with TNF-α suppression ( p = 0.025; β = − 0.235, 95% confidence interval [CI], − 0.436 to − 0.033). The L-arginine/ADMA ratio was also analyzed using multiple regression, adjusted for sex, age, peak creatine kinase levels, and smoking, showing a significant improvement in the ratio ( p = 0.018; β = 41.913, 95% CI, 10.337−73.491). Moreover, a weak negative correlation was suggested between the change in TNF-α levels and the change in l -arginine/ADMA ratio ( r = − 0.393, p = 0.058). PCSK9 inhibitor therapy in the early phase after AMI suppresses TNF-α levels and improves the l -arginine/ADMA ratio, potentially indicating anti-inflammatory and endothelial function-enhancing effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsMyocardial InfarctionAntibodies, Monoclonal, HumanizedHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTumor Necrosis Factor-alphaPercutaneous Coronary InterventionArginineBiomarkersTreatment OutcomeTime FactorsAnti-Inflammatory AgentsProprotein Convertase 9

Stichwörter der Autor:innen

l-arginine/asymmetric-dimethylarginineAcute myocardial infarctionProprotein convertase subtilisin/kexin 9 inhibitorTumor necrosis factor-α

Substanzen

PCSK9 InhibitorsalirocumabTumor Necrosis Factor-alphaPCSK9 protein, humanArginineBiomarkersAntibodies, Monoclonal, HumanizedN,N-dimethylarginineAnti-Inflammatory AgentsProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
  • Department of Internal Medicine, Matsunami General Hospital, Gifu, 501-6062, Japan.
  • Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. huzui@u-fukui.ac.jp.
  • Department of Clinical Nursing, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan. huzui@u-fukui.ac.jp.

Förderung

  • Japan Society for the Promotion of Science
  • University of Fukui

Zitieren

APA

Shimizu, T., Morishita, T., Uzui, H., Sato, Y., Kataoka, T., Miyoshi, M., Yamaguchi, J., Shiomi, Y., Ikeda, H., Tama, N., Hasegawa, K., Ishida, K., & Tada, H. (2025). Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction. Heart and Vessels. https://doi.org/10.1007/s00380-024-02473-8

Vancouver

Shimizu T, Morishita T, Uzui H, Sato Y, Kataoka T, Miyoshi M, et al. Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction. Heart and Vessels. 2025. doi:10.1007/s00380-024-02473-8

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Tomohiro and Morishita, Tetsuji and Uzui, Hiroyasu and Sato, Yusuke and Kataoka, Tatsuhiro and Miyoshi, Machiko and Yamaguchi, Junya and Shiomi, Yuichiro and Ikeda, Hiroyuki and Tama, Naoto and Hasegawa, Kanae and Ishida, Kentaro and Tada, Hiroshi},
  title = {Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction},
  journal = {Heart and Vessels},
  year = {2025},
  doi = {10.1007/s00380-024-02473-8}
}
Kostenlos starten →